Clinical trials: High Triglycerides
Familial Chylomicronemia, High Risk Severe Hypertriglyceridemia (SHTG)
Treatment Protocol of Plozasiran in Adults With High-Risk Severe Hypertriglyceridemia (SHTG) and in Adults and Adolescents With FCS
This is a treatment program for the use of plozasiran in adults (AROAPOC3-EAP-002) and adolescents (AROAPOC3-EAP-003) with familial chylomicronemia syndrome (FCS) as well as in adults (AROAPOC3-EAP-004) with high risk severe…
- Trial name
- NCT06796426
- Testing
- Plozasiran
- Where
- United States
- Sponsor
- Arrowhead Pharmaceuticals
Insulin Resistance, Hypertriglyceridemia
Novel Therapies for Metabolic Complications of Lipodystrophies
Lipodystrophies represent a therapeutic challenge with regards to the management of the diabetes, insulin resistance, hypertriglyceridemia and fatty liver which frequently present in conjunction with significant adipose tissue…
- Conditions
- Insulin Resistance, Hypertriglyceridemia, Diabetes, Hepatic Steatosis
- Trial name
- NCT00457938
- Testing
- low-fat diet ( Still recruiting ), Diet
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Texas Southwestern Medical Center
Waist, Hypertriglyceridemic
Dietary Incorporation of Lentils to Improve Metabolic Health
Approximately 40% of Americans are pre-diabetic or diabetic, mostly in the form of type 2 diabetes (T2D), which is heavily influenced by diet.
- Trial name
- NCT04448067
- Testing
- Dietary Lentil Intake, No Dietary Lentil CONTROL
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Montana State University
Hypertriglyceridemia
Evaluation of Efficacy and Safety of Combined Omacor (Omega-3-acid Ethyl Esters) and Simvastatin Therapy in Hypertriglyceridemic Subjects
The purpose of OM6 is to evaluate efficacy and safety of Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor] combined with simvastatin for lowering non-high-density lipoprotein cholesterol (non-HDL-C) in subjects with…
- Trial name
- COMBOS (NCT00246701)
- Testing
- Simvastatin, Simvastatin + Lovaza
- Volunteers
- 256 people
- Sponsor
- GlaxoSmithKline
Dyslipidemia, Coronary Heart Disease
Comparative Efficacy Evaluation of Lipids When Treated With Niaspan & Statin or Other Lipid-Modifying Therapies-COMPELL
The purpose of this study is to evaluate the effectiveness of first-line treatment using Niaspan (an extended release version of niacin) and statins versus other drugs that lower lipid levels, in subjects with elevated fat levels…
- Conditions
- Dyslipidemia, Coronary Heart Disease, Atherosclerosis, Stroke
- Trial name
- NCT00079638
- Testing
- Niacin, Atorvastatin, Simvastatin
- Volunteers
- 300 people
- Sponsor
- Kos Pharmaceuticals
Non-alcoholic Fatty Liver Disease (NAFLD)
Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients
The purpose of this study was to determine whether LCQ908 effectively lowers liver fat, as assessed by MRI and to assess its safety and tolerability profile in subjects with non-alcoholic fatty liver disease (NAFLD).
- Trial name
- NCT01811472
- Testing
- LCQ908
- Where
- 11 sites in United States
- Volunteers
- 52 people
- Sponsor
- Novartis Pharmaceuticals
Metabolic Syndrome, Familial Hypertriglyceridemia
Effects of FXR Activation on Hepatic Lipid and Glucose Metabolism
The purpose of this study is to determine whether chenodeoxycholic acid decreases de novo hepatic lipogenesis, hepatic fat content, hepatic triglyceride production and plasma triglyceride concentrations and improves hepatic…
- Conditions
- Metabolic Syndrome, Familial Hypertriglyceridemia, Familial Combined Hyperlipidemia
- Trial name
- NCT00465751
- Testing
- chenodeoxycholic acid
- Where
- Switzerland
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Hypercholesterolemia
Safety & Efficacy of a Combination Niacin ER/Simvastatin in Patients With Dyslipidemia: A Dose-Ranging Study - SEACOAST
The purpose of this study is to compare the effectiveness and safety of different doses of Niacin ER/Simvastatin (NS), in subjects with elevated fat levels in their blood (dyslipidemia).
- Trial name
- NCT00082251
- Testing
- Niacin extended release and simvastatin tablets
- Sponsor
- Kos Pharmaceuticals
Obesity
A Comparison of the Metabolic Effects of Fructose, Glucose, High Fructose Corn Syrup and Sucrose at Normal Population Consumed Levels in Adults Aged 20-60 Years Old
The purpose of this study is to investigate the acute and chronic effects of consumption fructose containing sugars and glucose in a real word setting when consumed in a manner and amount typical in the American diet.
- Trial name
- NCT01797042
- Testing
- Dietary Compliance
- Where
- United States
- Volunteers
- 366 people, healthy volunteers welcome
- Sponsor
- Rippe Lifestyle Institute
Diabetes Mellitus, Type 2, Obesity
Culturally-Adapted Diet for Puerto Rican Adults
This pilot project will determine whether a diet culturally-adapted to Puerto Ricans can effectively decrease cardiometabolic risk for diabetes.
- Conditions
- Diabetes Mellitus, Type 2, Obesity, Hypertension, Dyslipidemias
- Trial name
- NCT03975556
- Testing
- Culturally tailored food and diet advice, Standard healthy eating advice
- Where
- Puerto Rico
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Harvard School of Public Health (HSPH)
Prediabetes, Diabetes
Pilot Study of "Bottarga" Supplementation: A Little-known, Sustainable "Blue" Food
This pilot study aims to explore the potential benefits of consuming Greek bottarga (grey mullet fish roe) in individuals with at least one metabolic abnormality (low HDL cholesterol, high LDL cholesterol, high triglycerides…
- Conditions
- Prediabetes, Diabetes, High Cholesterol/Hyperlipidemia, Obesity & Overweight
- Trial name
- NCT06988462
- Testing
- Bottarga, Comparator
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cambridge Health Alliance
Obesity
Safety Study of LLF580 in Obese Volunteers
The purpose of the study is to evaluate the safety and tolerability of multiple doses of LLF580 administered subcutaneously over 3 months in obese subjects.
- Trial name
- NCT03466203
- Testing
- LLF580
- Where
- 7 sites in United States
- Volunteers
- 61 people
- Sponsor
- Novartis Pharmaceuticals